Early-Stage lung cancer drug trial halted before results
NCT ID NCT05275868
First seen Nov 10, 2025 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This early-phase study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had specific genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so we don't have full results on how well it worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering
New York, New York, 10017, United States
-
Memorial Sloan Kettering Onc. Dept
New York, New York, 10017, United States
-
NYU School of Medicine
New York, New York, 10015, United States
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Geneva, CH 1211, Switzerland
-
Novartis Investigative Site
Sankt Gallen, 9007, Switzerland
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Wash U School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.